Cancer “Moonshot” Launch Team Announced: Uncomfortable Ties To Anti-Industry Headlines
This article was originally published in RPM Report
Executive Summary
The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.